We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 625

Brexit Tracker: Keeping you informed - Issue two
  • McCann FitzGerald
  • Belgium, European Union, France, Ireland, United Kingdom, USA
  • November 11 2016

McCann FitzGerald is committed to keeping our clients up-to-date in relation to the legal


Pharmaceuticals: ingenious, but is it patentable?
  • Novagraaf
  • European Union, United Kingdom, USA
  • October 20 2016

In the final of our reports from the AIPPI Annual Congress that took place in Milan in September, we look at IP issues currently facing the


International Trade Compliance Update - September 2016
  • Baker & McKenzie
  • USA, Australia, Canada, European Union, United Kingdom
  • September 7 2016

On 19 August 2016, the Russian Federation notified the WTO that it intends to initiate negotiations pursuant to Paragraph 1143 of the Working Party


Life Sciences Legal Trends in Canada
  • Borden Ladner Gervais LLP
  • Canada, European Union, United Kingdom, USA
  • June 6 2016

The doctrine of “sound prediction” was ushered into Canadian law as a means to protect useful inventions. A review of the case law, however, reveals


Look before you leap: seeking to enforce your pharmaceutical patent may lead to unintended consequences
  • FPA Patent Attorneys
  • Australia, United Kingdom, USA
  • January 11 2016

It may not be just generic manufacturers seeking compensation when their product launch is found to be delayed by an originator wielding what is


Medical devices: recent developments in the UK and the US
  • Baker Botts LLP
  • United Kingdom, USA
  • July 21 2014

Whether a company develops physical tools for medical purposes or has pre-existing pharmaceuticals that can be commercialised in new ways via


IP challenges for the personalised medicines industry - gene claims (part 1)
  • Barker Brettell LLP
  • European Union, United Kingdom, USA
  • May 9 2013

When you go to the doctor you expect to be asked a lot of questions about your symptoms and your lifestyle, as the doctor builds up a clinical


U.K. jumps on “pay-to-delay” bandwagon
  • Fish & Richardson PC
  • United Kingdom, USA
  • April 24 2013

The U.K. Office of Fair Trading ("OFT") jumped on the "pay-to-delay" bandwagon last week when it issued a "Statement of Objections," indicating a


UK Supreme Court steps into line with Europe, but rejects U.S. approach
  • McDermott Will & Emery
  • European Union, United Kingdom, USA
  • November 30 2011

The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily


José P. Sierra
  • Fish & Richardson PC